Relapses driven by chemoresistant leukemic cell populations are the main cause of mortality for patients with acute myeloid leukemia (AML). Here, we show that the ectonucleotidase CD39 (ENTPD1) is upregulated in cytarabine (AraC)-resistant leukemic cells from both AML cell lines and patient samples in vivo and in vitro. CD39 cell surface expression and activity is increased in AML patients upon chemotherapy compared to diagnosis and enrichment in CD39-expressing blasts is a marker of adverse prognosis in the clinics. High CD39 activity promotes AraC resistance by enhancing mitochondrial activity and biogenesis through activation of a cAMP-mediated response. Finally, genetic and pharmacological inhibition of CD39 eATPase activity blocks the mitochondrial reprogramming triggered by AraC treatment and markedly enhances its cytotoxicity in AML cells in vitro and in vivo. Together, these results reveal CD39 as a new prognostic marker and a promising therapeutic target to improve chemotherapy response in AML. SIGNIFICANCE: Extracellular ATP and CD39-cAMP-OxPHOS axis are key regulators of cytarabine resistance, offering a new promising therapeutic strategy in AML. * *
INTRODUCTION
Chemotherapy resistance is the major therapeutic barrier in acute myeloid leukemia (AML), the most common acute leukemia in adults. AML is characterized by clonal expansion of immature myeloblasts and initiates from rare leukemic stem cells (LSCs). Despite a high rate of complete remission after conventional front-line induction chemotherapy (e.g. daunorubicin, DNR, or idarubicin, IDA plus cytarabine, AraC), the long-term prognosis is very poor for AML patients. To date, the 5-year overall survival is still about 30 to 40% in patients younger than 60 years old and less than 20% in patients over 60 years. This results from the high frequency of distant relapses (50 and 85% for patients younger and older of 60 years of age, respectively) caused by tumor regrowth initiated by chemoresistant leukemic clones (RLCs) and characterized by a refractory phase during which no other treatment has shown any efficacy thus far (1, 2) . Even with recent efficient targeted therapies that are FDAapproved or under clinical development, therapy resistance remains the major therapeutic barrier in AML. Therefore, understanding the molecular and cellular mechanisms driving chemoresistance is crucial for the development of new treatments eradicating RLCs and to improve the clinical outcome of these patients.
The biological basis of therapeutic resistance (drug efflux, detoxification enzymes, inaccessibility of the drug to the leukemic niche) currently represents an active area of research. However, the molecular mechanisms underlying AML chemoresistance are still poorly understood, especially in vivo. It is nevertheless increasingly recognized that the causes of chemoresistance and relapse reside within a small cell subpopulation within the bulk of leukemic cells. Supporting this idea, clinical studies have shown that the presence of high levels of CD34 + CD38 low/-CD123 + cells at diagnosis correlates with adverse outcome in AML patients in terms of response to therapy and overall survival (3, 4) . Consistent with these data, Ishikawa and colleagues (5) have observed that this population is also the most resistant to AraC treatment in vivo. As a first step towards successful therapeutic eradication of these RLCs, it is now necessary to comprehensively profile their intrinsic and acquired characteristics. We have recently established a powerful preclinical model to screen in vivo responses to conventional genotoxics and to mimic the chemoresistance and minimal residual disease observed in AML patients after chemotherapy (6) . Accordingly, we have fully analyzed the response to chemotherapy of leukemic cells in AraC-treated AML patientderived xenograft (PDX) mouse models. Surprisingly, we have found that AraC treatment equally kills both cycling and quiescent cells and does not necessarily lead to LSC enrichment in vivo. However, we observed that AraC chemoresistant leukemic cells present elevated oxidative phosphorylation (OxPHOS) activity and that targeting mitochondrial oxidative metabolism with OxPHOS inhibitors sensitizes resistant AML cells to AraC (6, 7) .
Consistent with our findings, several groups have also demonstrated that essential mitochondrial functions contribute to resistance to multiple treatments in other cancer types (8) (9) (10) (11) .
Hyperleukocytosis is a clinical condition observed in AML patients, which may lead to life-treatening complications such as leukostasis and is associated with a higher risk of relapse. Importantly, this condition is sustained by several mediators of inflammation, which were also reported to contribute to chemoresistance in AML (12) (13) (14) . Supporting this idea, a recent study reported that inhibition of the inflammatory chemoresistance pathway with dexamethasone improved AML patient outcome (15) . In line with these observations, recent work from our group (6) has highlighted a gene signature involved in the immune and inflammatory response after AraC treatment of PDX models in vivo. Amongst immune response mechanisms, the adenosine signaling pathway is one of the most prominent in cancer. CD39/ENTPD1 (ectonucleoside triphosphate diphosphohydrolase-1) is a member of the family of ectonuclotidases present on the outer surface of cells and a key component of the adenosine signaling pathway. Together with CD73, CD39 catalyzes phosphohydrolysis of extracellular adenosine triphosphate (eATP) and adenosine diphosphate (ADP) to produce adenosine, a recognized immunosuppressive molecule (16, 17) . Therefore, CD39 has a critical role in tumor immunosurveillance and inflammatory response. Furthermore, although other nucleoside triphosphate diphosphohydrolases (NTPDases) exist, CD39 appears to be the main NTPDase in T lymphocytes and regulatory T cells (18) . Recent lines of evidence have revealed high expression and activity of CD39 in several blood and solid tumors (such as head and neck cancer, thyroid cancer, colon cancer, pancreatic cancer, kidney cancer, testis cancer, and ovarian cancer), implicating this enzyme in promoting tumor growth and infiltration (19) and CD39 blockade was recently shown to enhance anticancer combination therapies in preclinical mouse models of solid tumors (20) . Furthermore, CD39 is frequently detected in primary tumor cells, including AML blasts, cancer-derived exosomes and tumorassociated endothelial cells. Notably, CD39 was reported to contribute to the immunosuppressive microenvironment in AML (21), while extracellular nucleotides (ATP, UTP) can inhibit AML homing and engraftment in NSG mice (22) .
In the present study, we employed computational analysis of transcriptomic datasets obtained from PDX models treated with AraC and from primary patient samples to identify new druggable and relevant cell surface proteins specifically expressed by RLCs. Among these genes, we uncovered CD39/ENTPD1 and confirmed that CD39 expression and activity are increased in residual AML cells post-chemotherapy in vitro, in vivo and in the clinical setting. Herein, we have also shown that high CD39-expressing resistant AML cells rely on an enhanced mitochondrial metabolism and are strongly dependent on the cAMP-PKA-PGC1α axis. Accordingly, targeting CD39 markedly enhanced AraC cytotoxicity in AML cell lines and primary patient samples in vitro and in vivo through the inhibition of mitochondrial OxPHOS function and this effect could be mimicked by inhibition of the PKA pathway.
Overall, this work shows that the mechanism of resistance to AraC involves CD39-dependent crosstalk between the energetic niche and AML mitochondrial functions through the CD39-cAMP-PKA signaling axis.
RESULTS

Enhanced CD39/ENTPD1 expression and activity are involved in early resistance to cytarabine in AML.
In order to identify new potential therapeutic targets involved in the onset of AraC resistance in vivo, we analyzed a previously identified signature of 68 genes that are significantly upregulated in residual AML cells from PDXs upon AraC treatment in vivo ((6); GSE97393). Bioinformatic analysis of this specific gene signature showed an enrichment in several key cancer and immune response signaling pathways, including 8 genes involved in the inflammatory response ( Supplementary Fig. S1A ). As inflammation has been previously shown to play a critical role in the development of chemoresistance and to be linked to a poor prognosis in AML (15), we focused on this latter group of genes. Within this subset, we identified five genes encoding plasma membrane proteins sensitive to existing inhibitors, thus representing relevant druggable targets of RLCs in vivo. Importantly, two of these genes, ecto-nucleoside triphosphate diphosphohydrolase-1 ENTPD1 (CD39) and fatty acid translocase CD36, were specifically overexpressed in AML cells compared to normal HSCs, highlighting their potential as therapeutic targets ( Supplementary Fig. S1B -C). As CD36 has already been shown by our and others groups to be a prognostic marker in myeloid leukemia (6, (23) (24) (25) , we focused on CD39. The eATPase CD39 is well known for its immunosuppressive and pro-angiogenic function in multiple cancer types (16, 17) . However, its role in AML cells and its contribution to AML chemoresistance are currently unknown.
Our gene expression data indicated that CD39 expression was upregulated in residual AML cells upon AraC treatment. To confirm that enhanced transcription correlated with increased surface protein levels, we studied CD39 cell surface expression in residual viable AML cells from the bone marrow of 25 PDXs following treatment with AraC (representative flow plot in Supplementary Fig. S2A ). As expected, we observed a significant cytoreduction of the total cell tumor burden in the bone marrow and spleen ( Next, we studied the kinetics of upregulation of CD39 in RLCs in vivo, during AraC treatment (day+3), immediately after the last dose of AraC treatment (day+5), and at day +8 in AMLxenografted NSG mice. Starting from day+5, we observed the appearance of RLCs with an increased CD39 expression ( Fig. 1H ). Of note, CD39-positive cells were not decreased at day 3 ( Fig. 1H ) and selection for CD39-positive cells occurred without genetic and mutational changes over time, as major founder mutations were present at diagnosis in patients and in the PDX throughout the same time course ( Supplementary Fig. S3F ). Altogether, these data strongly suggest that the CD39-positive phenotype may pre-exist before xenotransplantation and chemotherapy, and be selected and enhanced by AraC treatment in vivo. To test this hypothesis, we assessed whether sorted CD39 high and CD39 low cell subpopulations had a differential sensitivity to AraC treatment. Indeed, sorted CD39 high subsets from both MOLM14 and U937 AML cell lines pre-treated in vitro with AraC showed a significantly lower sensitivity to AraC with respect to their CD39 low counterparts ( Supplementary Fig. S3G ). Next, we compared ex vivo sensitivity to AraC of FACS-purified CD39 high and CD39 low fractions obtained from AML cells (from CLDXs and PDXs) pre-treated in vivo with AraC or vehicle.
Strickingly, therapy-naïve AML cells expressing high levels of CD39 also exhibited a significantly higher ex vivo EC 50 for AraC compared to the CD39 low subpopulation (Fig.1I ). On the other hand, residual AML cells derived from AraC-treated mice exhibited a lower basal sensitivity to the cytotoxic drug independent of the level of CD39 expression ( Fig.1I ).
Overall, our data indicate that a CD39 high phenotype characterizes in vitro and in vivo a subset of AML cells intrinsically resistant to AraC treatment. Importantly, this phenotype preexists and is amplified upon AraC chemotherapy in vivo.
Identification of CD39/ENTPD1 as a new prognostic marker associated with poor response to chemotherapy in AML patients.
In order to evaluate the clinical relevance of our findings, we analysed the expression of CD39 in AML patients. Analysis of a cohort of 162 AML patients at diagnosis indicated heterogeneous expression of CD39 ( Fig. 2A ). The expression of CD39 was not associated with the presence of specific recurrent mutations in AML ( Supplementary Fig. S4A ).
However, we observed a correlation between CD39 cell surface expression and FAB classification with a lower level of expression associated with the most undifferentiated AML subtypes ( Supplementary Fig. S4B ). This observation was also supported by the analysis of publicly available gene expression datasets from AML patients ( Supplementary Fig. S4C ).
We then followed 98 of these patients comparing CD39 cell surface expression at diagnosis (Dx) and at day 35 (D35) after intensive chemotherapy. In accordance with our preclinical model, we showed a significant tumor reduction or complete remission in most of the patients after treatment (Fig. 2B ), and demonstrated an overall increase in the percentage of CD39positive cells in the residual blasts from those patients at day 35 post-intensive chemotherapy ( Fig. 2C ). We then stratified these AML patients based on their fold enrichment (fold>1.5) in CD39-expressing cells upon chemotherapy, defining a group of "High CD39 ratio" (n=74) and "Low CD39 ratio" patients (n=24) ( Fig. 2D) . Strikingly, the "High CD39 ratio" patients displayed a significantly worse disease-free survival compared to the "Low CD39 ratio" group ( Fig. 2E ). This survival disadvantage was even more evident when focusing on the group of patients younger than 60 years of age ( Fig. 2F ).
Finally, we investigated whether CD39-positive cells expansion upon chemotherapy could further stratify patients classified in favorable, intermediate and high cytogenetic risk groups. The increase in CD39-positive cells did not significantly improve the prognostic classification of intermediate and high cytogenetic risk patients ( Supplementary Fig. S5 ).
However, this analysis revealed that AML patients from the favorable cytogenetic risk subgroup but characterized by a marked increase in CD39-expressing cells upon chemotherapy, displayed a significantly higher rate of short-term relapse and poorer clinical outcome ( Fig. 2H ).
Overall, these findings highlight the clinical relevance of our results obtained in PDXs and CLDXs and define CD39 as a marker of poor response to therapy and adverse prognosis in AML patients.
CD39 expression is associated with with higher mitochondrial activity and biogenesis.
As previous studies have demonstrated that drug-resistant AML cells exhibit high
OxPHOS function and gene signatures in vivo (6, 9, 10) , we investigated whether an OxPHOS gene signature was enriched in the transcriptomes of AML cells with high CD39 expression.
We confirmed a positive correlation between CD39 RNA expression and our previously defined "High OxPHOS" gene signature (6) making use of two independent transcriptomic databases from AML patients that we stratified as CD39 low and CD39 high (GSE97393: NES=-1.84, FDRq<0.001 and GSE10358: NES=-1.50, FDRq=0.004; respectively; Fig. 3A and Supplementary Fig. S6A ). We then compared the metabolic status and mitochondrial activity of primary AML cells from patients with high or low levels of CD39 expression ( Supplementary Fig. S6B -C). Accordingly, primary cells from CD39 high AML patients displayed increased CD39 eATPase activity compared to CD39 low patients ( Fig. 3B ) and this was associated with a modest increase in mitochondrial membrane potential (MMP) and larger increase in basal oxygen consumption rate (OCR, Fig. 3C -D). We then sorted the low and high CD39 cell fractions from one of our PDXs (Ps8) after treatment in vivo with AraC or PBS ( Supplementary Fig. S6D ). In line with our previous results on the primary patient samples, the ex vivo analysis of the metabolic status and OCR of the two cell subsets showed increased basal and maximal uncoupler-stimulated respiration, as well as ATPlinked respiration in CD39 high fractions compared to CD39 low fractions from PBS treated mice ( Fig. 3E and Supplementary Fig. S6E -H). In accordance with our previously published data (6) , AraC treatment resulted in the selection of residual viable AML cells with substantially increased basal and maximal uncoupler-stimulated OCR as well as ATP-linked OCR ( Fig. 3E and Supplementary Fig. S6E -H). Overall, this indicated that increased levels of CD39 were associated with an enhanced mitochondrial activity and OxPHOS function in AML cells, which we previously identified as a feature of AraC resistant AML cells.
In order to specifically study the direct effect of modulating CD39 expression on AML cell metabolism, we transduced the AML MOLM14 cell line with viral vectors expressing two different shRNAs targeting CD39. Transduction of MOLM14 with the shCD39-expressing lentiviral vectors resulted in efficient silencing of the ectonucleotidase both at the mRNA level and at the protein level ( Supplementary Fig. S7A-B ), leading to a significant down-regulation of the expression of this marker at the cell surface ( Supplementary Fig. S7C ). Silencing of CD39 resulted in a dramatic decrease in both basal and ATP-linked OCR in MOLM14 ( Fig.   3F -H), which translated into a reduced generation of mitochondrial-derived ATP (Fig. 3I ).
This decreased mitochondrial OxPHOS activity was associated with a reduced expression of subunits of the ETC complexes and of well-known effectors of mitochondrial biogenesis (i.e. NRF1, PGC1) ( Fig. 3J ). Overall, these results indicate that CD39 positively controls mitochondrial function and oxidative phosphorylation at least in part by controlling the expression of the key transcriptional activators NRF1 and PGC1 promoting mitochondrial biogenesis.
Pharmacological inhibition of CD39 ectoducleotidase activity inhibits the metabolic reprogramming associated with AraC resistance and enhances AML cell sensitivity to
AraC in vitro.
Next, we sought to determine whether inhibition of CD39 activity by polyoxometalate 1 Altogether, our results strongly suggest that CD39 activity directly affects AML cell sensitivity to AraC through the regulation of mitochondrial function.
Cytarabine residual cells enhance OxPHOS metabolism through the activation of the
CD39-cAMP-PKA-mediated mitochondrial stress response in AML.
Because our results strongly support the assertion that CD39 expression influences mitochondrial OxPHOS, we sought to explore signaling pathways downstream of CD39 that may promote OxPHOS metabolism and chemoresistance. Therefore, we performed an independent RNA expression experiment to characterize global changes induced by shCD39
in the therapy-resistant MOLM14 AML cell line. A total of 152 genes were significantly differentially expressed in MOLM14 upon silencing of CD39 (42 up-regulated, 110 downregulated; FDR>1.25, log2(fold-change)>1.0; Fig. 5A and Supplementary Table S2 ). In line with our metabolic assays, gene set enrichment analysis (GSEA) indicated that CD39 loss in DNA repair, responses to stress/stimuli, metabolism and signaling (p<0.01; Fig. 5D ; Supplementary Fig. S8B ). Interestingly, GSEA for known signaling pathways revealed a significant positive enrichment of genes involved in the cAMP-PKA pathway, a master regulator of mitochondrial homeostasis and oxidative stress response, and of CREB/ATF genes in transcriptomes of AML patient cells with highest CD39 expression compared to AML patient cells with lowest CD39 expression ( Fig. 5E ; Supplementary Fig. S6A ).
Moreover, transcription factor enrichment analysis identified signatures of multiple transcription factors playing key roles in mitochondrial homeostasis and stress response (such as ATF4/6, PARP1 and E2F1; Supplementary Fig. S8C ). Based on these observations, we formulated the hypothesis that the activation of the cAMP-PKA-mediated stress response pathway was controlling enhanced mitochondrial activity and biogenesis driven by CD39 up-regulation upon AraC treatment in AML cells. Therefore, we investigated the modulation of the c-AMP-dependent PKA signaling pathway upon AraC treatment of MOLM14 and inhibition of CD39 ( Supplementary Fig. S8E-F These results strongly support the hypothesis that CD39 activity greatly influences AraC cytotoxicity through modulation of mitochondrial function in a cAMP-PKA-dependent manner.
Targeting CD39 enhances AraC chemotherapy efficacy in vivo
Our data suggest that inhibiting CD39 activity may be a promising therapeutic strategy to enhance chemotherapy response of AML cells in vivo. In order to test this hypothesis, we generated NSG mice-based CLDX and PDX models from AML cell lines and primary patient cells, respectively. We then tested the consequences of CD39 repression on the response of 
DISCUSSION
Poor overall survival is mainly due to frequent relapse caused by RLCs in AML patients (2, 27) . While recent studies have highlighted new mechanisms of drug resistance in AML especially in vivo (6, 28, 29) , their clinical applications are still unresolved or under assessment. New therapies that specifically target and effectively eradicate RLCs represent an urgent medical need. In this work, we have identified the cell surface eATPase ENTPD1/CD39 and its downstream signaling pathway as a new critical and druggable target involved in the resistance to cytarabine in AML. We showed that CD39 was overexpressed in residual AML cells post-chemotherapy from both 25 PDX models and 98 patients in the clinical setting. CD39 is also highly expressed in several human solid tumors, in which it was shown to actively contribute to cancer cell proliferation, dissemination and metastatic process (30, 31) . In the context of AML, our data supports a model in which AraC treatment induces the selection and amplification of CD39 expressing pre-existent and intrinsically resistant leukemic cells. We have furthermore observed that drug-induced increase in CD39 expression is associated with a poor response to AraC in vivo, persistence of residual disease, and with poor overall survival in AML patients, especially in the younger subgroup of patients.
While many pro-survival and anti-apoptotic signals are activated in AML by the stroma (32, 33) , nucleotides and nucleosides have emerged as important modulators of tumor biology. In particular, ATP and adenosine are major signaling molecules present in the tumor microenvironment. A growing body of evidence shows that when these molecules are released by cancer cells or surrounding tissues, they act as prometastatic factors, favoring tumor cell migration and tissue colonization. Interestingly, eATP elicits different responses in tumor cells, including cell proliferation (34, 35) , cell death (36, 37) and metastasis (38, 39) . Furthermore, several studies described a direct cytotoxicity of eATP on different tumor cell types such as melanoma, glioma and colon cancer cells (40) (41) (42) . In AML, eATP was reported to reduce human leukemia growth in vivo and enhance the antileukemic activity of AraC (22) . The increase of CD39 expression occurred at early time points of the chemotherapeutic response and residual disease processes in PDXs and patients likely due to enrichment in eATP released from dying and apoptotic cells upon AraC treatment. Of note, high expression of CD39 was associated with a higher activity resulting in eATP hydrolysis to support AML regrowth and relapse. Bone marrow microenvironment is a key regulator of leukemia growth and has many chemoprotecting effects for AML cells (23, 43, 44) . We and others have shown that mitochondrial OxPHOS is a crucial contributing factor of AML chemoresistance and its inhibition sensitizes cells to AraC treatment (6, 7, 45) . This is mainly due to an increase in respiratory substrate availability and in mitochondrial machinery transfer from the BM-MSCs (46,47). Here we unveil an additional mechanism supporting mitochondrial high OxPHOS activity in reponse to AraC treatment through the enhancement Previous studies have reported the pleiotropic roles of cAMP signaling and its major downstream effector PKA in different cancers including AML. Perez and colleagues showed that cAMP efflux from the cytoplasm protects AML cells from apoptosis (52) . Similarly, others reported cAMP mediated protection of acute promyelocytic leukemia against anthracycline (53) or against arsenic trioxide-induced apoptosis (54) . PKA, whose activation initiates an array of transcriptional cascades involved in the immune response, cell metabolism and mitochondrial biogenesis, is one of the main and canonical downstream effectors of cAMP signaling. Intriguingly, cAMP-PKA signaling can be localized not only on the plasma membrane or nucleus but also on the outer mitochondrial membrane or matrix (55) .
Mitochondrial cAMP signaling was shown to regulate cytosol-mitochondrial crosstalk, mitochondrial biogenesis and morphology, mitochondrial dynamics, mitochondrial membrane potential, TCA cycle activities and ETC complexes in basal and stress conditions such as starvation or hypoxia (56) . Of note, cAMP signaling is activated as integral part of the mitochondrial stress response that allows the rewiring of cellular metabolism in the presence of cellular damage and oxidative stress conditions. In this context, PGC1and NRF1/2 activation leads to an increase in expression and assembly of respiratory chain supercomplexes and a boost in oxidative phosphorylation activity, allowing dynamic adaptation of mitochondrial functions to survive adverse conditions (57) . These studies establish a mechanistic link between cAMP, PKA and PGC1 in the regulation of mitochondrial biogenesis/function through the activation of mitochondrial stress response.
Collectively, our data suggest that CD39 activity, through the control of extracellular levels of ADP and AMP and the downstream activation of the cAMP-PKA pathway, may trigger a process similar to the mitochondrial stress response in resistant leukemic cells to rewire their energetic metabolism and enhance PGC1-mediated mitochondrial biogenesis and OxPHOS activity upon chemotherapy treatment (Fig. 7) . In this context, we propose that eATP and CD39 are key actors in a novel signaling mechanism implicated in AML chemoresistance to AraC and that targeting CD39 would be a promising therapeutic strategy to sensitize AML cells to AraC. In light of the recently recognized "immune checkpoint mediator" function of CD39 that interferes with anti-tumor immune responses, our data further suggest the existence of a critical crosstalk between AML cells and their immune and stromal microenvironment mediated by extracellular nucleotides and/or CD39 in the response to therapy of AML cells. In this context, blocking CD39 activity could have a double edge therapeutic benefit by both dampening the metabolic reprogramming supporting AraC cell-autonomous resistance and disrupting the immune escape mechanisms.
In conclusion, our study uncovers a non-canonical role of CD39 on AML resistance (Fig.7) , and provides a strong scientific rationale for testing CD39 blockade strategies in combination with AraC treatment in clinical trials for patients with AML. Because CD39-blocking monoclonal antibodies are already in clinical trials as a single agent and in combination with an approved anti-PD-1 immunotherapy or standard chemotherapies for patients with lymphoma or solid tumor malignancies, we expect that these findings have the potential for rapid translation of our proposed combination therapy with CD39 as a putative predictive biomarker into the clinic. For control, NSG mice were treated daily with IP injection of vehicle, PBS 1X. Mice were monitored for toxicity and provided nutritional supplements as needed.
METHODS
Primary cells from AML patients
POM-1 or ARL67156 was administrated to xenografted mice by IP injection every other day for two weeks. The time of dissection was fifteen days after the last dose of POM-1 (or ARL67156) or 8 days for AraC, two days after the last dose of each treatment.
Assessment of leukemic engraftment
NSG mice were humanely killed in accordance with European ethic protocols. Bone analysis and short tandem repeat (STR) profiling. Furthermore, the mutation status was also verified by targeted re-sequencing of a panel of 40 genes frequently mutated in AML as described in Supplementary methods. Clinical and mutational features of our AML cell lines are described in Supplementary Table S1 . These cell lines have been routinely tested for Mycoplasma contamination in the laboratory.
Statistical analyses
We assessed the statistical analysis of the difference between 2 sets of data using non-parametric Mann-Whitney test one-way or two-way (GraphPad Prism, GraphPad). The
Mantel-Cox log-rank test was used for statistical assessment of survival. P values of less than 0.05 were considered to be significant (* P<0.05, ** P<0.01 and *** P<0.001).
For in vitro and in vivo analyses of cytarabine residual disease and CD39 studies, see Supplementary Methods. RNA-seq data are available at the Gene Expression Omnibus under the accession number GSE136551.
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